Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 234Breast Neoplasms 234Prostatic Neoplasms 172Multiple Myeloma 154Neoplasms 135Colorectal Neoplasms 126Leukemia, Myeloid, Acute 123Lung Neoplasms 109Neoplasm Metastasis 101Squamous Cell Carcinoma of Head and Neck 94Carcinoma, Hepatocellular 91Melanoma 89Lymphoma 85Triple Negative Breast Neoplasms 77Pancreatic Neoplasms 76Ovarian Neoplasms 72Sarcoma 71Brain Neoplasms 66Lymphoma, Large B-Cell, Diffuse 65Carcinoma, Renal Cell 65Recurrence 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Head and Neck Neoplasms 56Lymphoma, Non-Hodgkin 55Leukemia, Lymphocytic, Chronic, B-Cell 55Stomach Neoplasms 52Hematologic Neoplasms 52Endometrial Neoplasms 52Urinary Bladder Neoplasms 51Rectal Neoplasms 50

Interventions

enasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Esthesioneuroblastoma, Olfactory × 90 days × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

NCT07527169 2026-04-14

A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
16 enrolled
CNS

Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡